Grace Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed Jun 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Jun 18, 2026

GRCE$1.86-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

Stockholders’ Equity

	Common stock
(Expressed in thousands except share data)	Number	Amount	Additional paid-in capital	Accumulatedother comprehensiveloss	Accumulated deficit	Total stockholders' equity
$ · $ · $ · $ · $
Balance, March 31, 2025	13,718,106	1	293,334	(6,038)	(220,687)	66,610
Net loss	—	—	—	—	(7,793)	(7,793)
Stock-based compensation	—	—	798	—	—	798
Issuance of common stock upon exercise of pre-funded warrants	960,456	—	—	—	—	—
Issuance of common stock upon exercise of common warrants	1,345,464	—	4,281	—	—	4,281
Balance at March 31, 2026	16,024,026	1	298,413	(6,038)	(228,480)	63,896

	Common stock
(Expressed in thousands except share data)	Number	Amount	Additional paid-incapital	Accumulatedother comprehensiveloss	Accumulated deficit	Total stockholders' equity
$ · $ · $ · $ · $
Balance, March 31, 2024	9,399,404	1	278,899	(6,038)	(211,119)	61,743
Net loss	—	—	—	—	(9,568)	(9,568)
Stock-based compensation	—	—	730	—	—	730
Issuance of common stock upon cashless exercise of pre-funded warrants	740,457	—	—	—	—	—
Issuance of common stock and warrants through private placement, net of offering costs	3,252,132	—	13,705	—	—	13,705
Issuance of common stock upon exercise of common warrants	326,113	—	—	—	—	—
Balance at March 31, 2025	13,718,106	1	293,334	(6,038)	(220,687)	66,610

Consolidated Statements of

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.